Issue Date: November 19, 2012
Funding Is Secured At Visterra, Pearl
Visterra has completed a $26 million Series A financing round. The Bill & Melinda Gates Foundation and Omega Funds joined three existing investors in the effort. Cambridge, Mass.-based Visterra will use the funds to develop its pipeline of antibodies to treat infectious diseases. Separately, Pearl Therapeutics has secured $65 million in its latest financing round, which involved existing investors. The Redwood City, Calif.-based firm will use the cash to initiate a Phase III study of PT003, a treatment for chronic obstructive pulmonary disease.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society